| Rubicon Technology, Inc. Q1 2010 Earnings Call Transcript Rubicon Technology, Inc. (RBCN)Q1 2010 Earnings Call TranscriptApril 29, 2010 5:00 pm ETComplete Story » seekingalpha.com |
Ventas to Acquire Lillibridge Healthcare Ventas agreed to acquire privately held Lillibridge Healthcare and real-estate interests in 95 medical office buildings and ambulatory facilities for between $300 million and $400 million. online.wsj.com |
Biogen Idec Inc. Q2 2010 Earnings Call Transcript Biogen Idec Inc. (BIIB)Q2 2010 Earnings CallJuly 20, 2010 8:30 AM ESTComplete Story » seekingalpha.com |
BioReference Laboratories, Inc. to Speak at the UBS Global Life Sciences Conference [Business Wire] - ELMWOOD PARK, N.J.----BioReference Laboratories, Inc. announced today that Marc D. Grodman M.D., President and Chief Executive Officer, is scheduled to speak at the 2010 UBS Global Life Sciences Conference on Monday, September 20, 2010, at The Grand Hyatt Hotel located in New York, NY. us.rd.yahoo.com |
Court Ruling Increases Pressure on Sanofi to Buy Genzyme The Burrill Report submits: By Michael Fitzhugh Sanofi-Aventis (SNY) has lost a legal battle intended to fend off generic competition for Taxotere, a cancer medicine that generated more than 8 percent of its net pharmaceutical sales in 2009. The U.S. District Court ruling invalidates two patents that would have protected Taxotere from generic competition until 2013. Hospira and Apotex, two companies planning to market generic versions of the drug, will be happy to get rolling sooner than that. But for Sanofi, the ruling could have larger implications. Accelerated competition for Taxotere could erode revenue sooner than expected, ratcheting up the pressure to replace it by acquiring Genzyme (GENZ). Genzyme's board rebuffed Sanofi's August offer of $69 per share as too meagerly priced. But already rumors of Sanofi's intentions to raise that bid have surfaced. Sanofi's board could meet within days to approve a higher bid for Genzyme, according to Dow Jones Newswires. A higher bid could prompt Genzyme to allow Sanofi access to confidential financial information on its books and conduct due diligence on the company. Complete Story » seekingalpha.com |